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Edited by Lukas HuberAbstract Recently, negative eﬀects of phosphatase in tumori-
genesis and metastasis have been suggested in various tumor
types. In this study, we showed that RhoA activation modulated
phosphatase during senescence-like arrest in human prostate
cancer cells. Under senescence-inducing condition, decreased
Erk phosphorylation was detected in caRhoA-transfected cells
and inactivation of Erk, but not p38, prevented doxorubicin-in-
duced cell senescence. Cells were induced to senescence by inhi-
bition of phosphatase activity (VHR, MKP3, or PP2A) without
additional cellular stress. Of interest, caRhoA prevented doxoru-
bicin-induced decrease of phosphatase. Thus, we postulate that
RhoA signaling may protect cells against cellular senescence
by maintaining phosphatase activity and Erk dephosphorylation.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Ras homologous A (RhoA), which is a low molecular weight
GTPase of the Ras superfamily, is involved in promoting cel-
lular proliferation [1]. Various studies have shown that RhoA
signaling is important for malignant progression. For example,
RhoA is overexpressed in many aggressive cancers, the protein
expression levels of RhoA-like proteins have been correlated
with the extent of malignancy [2–4], and RhoA is constitutively
activated in breast cancer cell lines [5].
Senescence in human cells is associated with speciﬁc physio-
logical and morphological changes, including reduced prolifer-
ation, ﬂattening and enlargement of the cell shape, and the
appearance of senescence-associated b-galactosidase (SA-b-
Gal) activity [6]. Tumor cells tend to undergo senescence in re-
sponse to damage, as demonstrated by the observation that
low doses of chemotherapeutic agents induced senescence-like
phenotypes in several tumor cell lines [7,8]. The growth arrest
seen during senescence has been associated with upregulation
of various negative mediators of the cell cycle, including p53,*Corresponding authors. Fax: +82 2 3410 6808 (C. Park); +82 2 3410
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p27Kip1 and p16INK4a [9–12]. Tumor cells can evade senes-
cence, and this is linked to malignant progression or sensitivity
to chemotherapy. To improve our understanding of how
malignant cells escape senescence, it may be useful to deﬁne
the pathway(s) involved in this process.
In this report, we showed that RhoA protein-dependent sig-
naling inhibited Erk phosphorylation and senescence-like ar-
rest in human prostate cancer cells. RhoA-mediated
suppression of growth arrest was associated with induction
of hypophosphorylated-Rb, p21 protein, and p27 protein.
Knockdown of Erk using siRNA or an Erk inhibitor reduced
doxorubicin-induced growth arrest, whereas knockdown or
inhibition of phosphatase induced growth arrest. Furthermore,
transient expression of constitutively active RhoA (caRhoA)
protected phosphatase activity from doxorubicin-induced inhi-
bition, indicating that RhoA-mediated suppression of growth
arrest might be due to maintenance of phosphatase activity
and Erk dephosphorylation.2. Materials and methods
2.1. Cell culture and materials
The PC-3 human prostate cancer cell line was purchased from the
American Type Culture Collection (Rockville, MD), and the cells were
cultured in RPMI-1640 (Gibco BRL, Grand Island, NY) supple-
mented with 10% heat-inactivated fetal bovine serum (Gibco BRL).
Doxorubicin was purchased from Sigma (St. Louis, MO). GGTI298,
C3 exoenzyme, SB203580, PD98059 and okadaic acid were purchased
from Calbiochem (La Jolla, CA). Full-length caRhoA and dnRhoA
were constructed from normal ﬁbroblast mRNA using a reverse tran-
scription-PCR-based cloning technique, and the resulting fragments
were inserted into pcDNA3.1 (Invitrogen, Carlsbad, CA). The 21-
nucleotide-long siRNAs corresponding to p38, Erk, VHR, MKP3
and a control scrambled siRNA were purchased from Dharmacon
(Lafayette, CO). Cells were transfected with siRNA or DNA using
the Amaxa electroporation system, according to the supplier’s protocol
(Amaxa, Gaithersburg, MD).
2.2. Cell cycle analysis
The cells were then trypsinized, washed twice with ice-cold phos-
phate-buﬀered saline (PBS), and ﬁxed with 2 ml of 70% ethanol. The
ﬁxed cells were centrifuged at 200 · g for 10 min, and the resulting pel-
lets were washed twice with PBS and then incubated with 100 lg/ml
propidium iodide (PI) (Sigma) and 100 lg/ml RNase at 37 C for
30 min. The percentages of cells in the various cell cycle phases were
measured using a FAC-Star ﬂow cytometer (Becton-Dickinson, San
Jose, CA) and analyzed with the provided software (e.g. Lysis II and
Cellﬁt).blished by Elsevier B.V. All rights reserved.
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Total cell extracts were obtained using lysis buﬀer containing 50 mM
Tris–HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, 1% NP40, and 1· pro-
tease inhibitors (Roche Applied Science, Indianapolis, IN), and pro-
teins were quantiﬁed using the micro BCA protein reagent (Pierce,
Rockford, IL). The utilized primary antibodies were as follows: p21
(C-19, Santa Cruz), p27 (C-19, Santa Cruz), Rb (BD Pharmingen),
hypophosphorylated Rb (BD Pharmingen), E2F-1 (KH95, Santa
Cruz), cdc2 (17, Santa Cruz), cyclin A (H-432, Santa Cruz), c-Myc
(9E10, Santa Cruz), RhoA (26C4, Santa Cruz), Erk (Santa Cruz),
p38 (Santa Cruz), phospho-Erk (Cell Signaling Technology, Beverly,
MA), phospho-p38 (Cell Signaling Technology), lamin A (Oncogene),
Hsp90 (H114, Santa Cruz) and b-actin (Sigma). Horseradish peroxi-
dase-conjugated goat anti-rabbit immunoglobulin G (IgG) (Santa
Cruz) was used as the secondary antibody. Reactive proteins were visu-
alized using an ECL kit (Amersham Life Sciences, UK).
2.4. Separation of cytosolic and nuclear fractions
Cells were scraped into buﬀer A (10 mM HEPES, 1.5 mM MgCl2,
10 mM KCl, 0.5% NP-40, 2 mM Na2VO4, 5 mM NaF and protease
inhibitors), incubated at 4 C for 15 min and then centrifuged at
5000 · g for 10 min. The supernatant was collected as the cytosolic
fraction. The pellet was washed with NP-40-free buﬀer A and then cen-
trifuged at 5000 · g for 10 min. The supernatant was discarded, and
the pellet was resuspended in buﬀer B (20 mM HEPES, 1.5 mM
MgCl2, 400 mM NaCl2, 2 mM EDTA, 10% glycerol, 2 mM Na2VO4,
5 mM NaF, and protease inhibitors). The suspension was incubated
for 60 min at 4 C and then centrifuged at 15000 · g for 30 min. The
ﬁnal supernatant was collected as the nuclear fraction.
2.5. RT-PCR analysis
For reverse-transcription, 2 lg of RNA was treated with RNase-free
DNase, and cDNA was obtained using Moloney murine leukemia
virus reverse transcriptase. The generated cDNA was PCR ampliﬁed
using primers speciﬁc for VHR (5 0-CAAGCTGCAGAAACT-
AGGCA-3 0 and 5 0-CTGTCATTGAGCTGGCAGAG-30) or MKP3
(5 0-AGTTTTTCCCTGAGGCCATT-3 0 and 5 0-ACACACAAAG-
AAAGCAGCCC-3 0). The ampliﬁcation conditions consisted of 30
cycles of 30 s at 94 C, 30 s at 60 C, and 30 s at 72 C. Actin was
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Fig. 1. Eﬀect of RhoA on cellular senescence-like arrest in the PC-3 prostate c
1 lg/ml C3 exoenzyme, or 5 days after transient transfection of 50 nM siRh
light microscopy, and photographed at 200· magniﬁcation. (B) After transfec
doxorubicin for 5 days and then analyzed for SA-b-gal staining. (C) caRhoA
DNA damage-induced senescence. PC-3 cells were treated with 10 nM doxo
related protein expression by Western blot analysis. Levels of ectopic caR
antibody. b-Actin was used as a loading control.2.6. Senescence determination by senescence-associated (SA) b-gal
staining
SA-b-Gal staining was performed as previously described [8]. Senes-
cence was scored based on the percentage of the population that exhib-
ited a SA-b-Gal activity, and the results were photographed under
phase contrast microscopy.2.7. Protein tyrosine phosphatase assay
Protein tyrosine phosphatase activity was measured in a 96-well
plate coated with poly-(Glu4-pTyr) peptides, according to the manu-
facturer’s protocol (Universal Tyrosine Phosphatase Assay kit, Ta-
kara). Protein tyrosine phosphatase activity was quantiﬁed from a
standard curve obtained using recombinant CD45 tyrosine phospha-
tase as provided in the kit.3. Results
3.1. RhoA signaling inhibits cell cycle arrest and cellular
senescence
To determine whether RhoA aﬀects senescence-like arrest,
prostate cancer cells were treated with various reagents and
stained for SA-b-gal, a biomarker for senescent cells [13]. Sig-
niﬁcant SA-b-gal staining was detected in PC-3 cells harvested
after 5 days incubation with doxorubicin, RhoA inactivator
GGTI-298 or C3 exoenzyme, or 5 days after transfection with
plasmids encoding siRhoA or dominant negative RhoA [14,15]
(Fig. 1A). Irreversible senescence-phenotype of cancer cells in
response to doxorubicin has been demonstrated previously
by Chang et al. [7,8]. To examine whether RhoA can block
doxorubicin-induced senescence-phenotype, we generated a
constitutively active RhoA (caRhoA) expression system in
PC-3 cells and performed a SA-b-gal assay following doxoru-
bicin treatment of these cells (Fig. 1B). The caRho-A-express-
ing cells showed signiﬁcantly reduced growth arrest after 5   C3 exo 
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ancer cell line. (A) After 5 days of incubation with 20 lMGGTI-298 or
oA or dnRhoA, cells were ﬁxed for SA-b-gal staining, analyzed under
tion with control plasmid or caRhoA, cells were incubated with 10 nM
modulates cell cycle- and senescence-related protein expression during
rubicin, harvested on the indicated days, and evaluated for cell cycle-
hoA expression were examined by immunoblotting with an anti-myc
3802 C. Park et al. / FEBS Letters 581 (2007) 3800–3804days incubation with 10 nM doxorubicin (Fig. 1B, P < 0.0001).
In contrast, mock (vector)-transfected cells or untransfected
PC-3 cells underwent irreversible growth arrest following
doxorubicin treatment, as indicated by increased SA-b-gal
staining.
The caRhoA-induced inhibition and siRhoA- or dnRhoA-
induced induction of SA-b-gal staining led us to investigate
the eﬀect of RhoA signaling on the expression levels of cell cy-
cle- and senescence-related proteins in p16-null PC-3 cells [8].
In agreement with the changes in senescence and cell morphol-
ogy observed by light microscopy (Fig. 1B) and cell cycle anal-
ysis (Fig. 1C), the results showed that caRhoA profoundly
aﬀects cell cycle arrest, in association with upregulation of cell
cycle regulators (E2F1, cyclin A and cdc 2), and downregula-
tion of CDK inhibitors (p21 and p27) and hypophosphoryla-
tion of Rb.
3.2. Inhibition of Erk signaling in cellular senescence
To determine whether the expression or phosphorylation of
MAPK is critical for senescence-like arrest, PC-3 cells were ex-
posed to PD98059, SB203580, sip38 or siErk. As shown in
Fig. 2A, incubation with 20 lM PD98059 signiﬁcantly blocked
the growth arrest caused by doxorubicin exposure, as com-
pared to untreated control cells (P < 0.0001). In contrast,
growth arrest was not signiﬁcantly inhibited by the addition
of 10 lM SB203580. Addition of Erk-targeting siRNA signif-DMSO PD98059 SB203580
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Fig. 2. Expression and phosphorylation of Erk is critical for DNA damage-in
PD98059 or 10 lM SB203580 in the presence or absence of 10 nM doxorubic
p38 or Erk in PC-3 cells. After 5 days incubation with 10 nM doxorubicin,
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Fig. 3. Eﬀect of caRhoA on doxorubicin-induced MAPK signaling. (A) PC-
Crude nuclear- and cytosolic fractions were immunoblotted with the indicate
nuclear and cytosolic proteins, respectively.icantly prevented senescence-like arrest, as compared to un-
treated control cells (Fig. 2B, P = 0.0027). In contrast,
growth arrest was not signiﬁcantly inhibited by the addition
of p38-targeting siRNA. Addition of PD98059, SB203580,
sip38 or siErk to PC-3 cells in the absence of doxorubicin
did not induce senescence-like arrest. These results collectively
indicate that inhibition of Erk phosphorylation selectively
blocks growth arrest of PC-3 cells.3.3. Active RhoA inhibits Erk phosphorylation
As shown in Fig. 3, transient expression of caRhoA in doxo-
rubicin-treated prostate cancer cell lines markedly reduced the
phosphorylation levels of Erk but not p38, as compared to lev-
els in doxorubicin-treated control cells. The other major
MAPK, c-Jun N-terminal protein kinase (JNK), was not ex-
pressed at detectable levels in our system. Next, we examined
whether caRhoA aﬀected mitogen-activated protein kinase
(MAPK) signaling, and found that caRhoA inhibited the
induction of phosphorylated Erk in both nuclear and cytosolic
cell fractions (Fig. 3).3.4. RhoA modulates phosphatase thereby suppressing cellular
senescence
Since Erk inhibitor reversed doxorubicin-induced senescence
in our system, and Erk has been identiﬁed as a substrate forsiScr siErksiScr sip38
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Fig. 4. RhoA-modulated protein phosphatase activity is critical for senescence-like arrest. (A) Knockdown of VHR or MKP3 induces cellular
senescence in PC-3 cells. Cells were incubated with 50 nM siVHR or siMKP3 for 5 days. RT-PCR analysis demonstrated eﬃcient knockdown of
VHR or MKP3 in PC-3 cells. (B) Okadaic acid induces Erk phosphorylation and senescence-like arrest. Cells were treated for 8 h with indicated
doses of the PP2A inhibitor, okadaic acid, incubated for ﬁve more days in fresh media, and then ﬁxed for SA-b-gal staining. (C) After transfection
with control plasmid or caRhoA, cells were incubated with 10 nM doxorubicin for 5 min and then analyzed for PTP activity (U/lg protein), as
described in Section 2. (D) Knockdown of VHR overrides caRhoA expression for induction of senescence-like arrest. Cells were transfected with
caRhoA plus siVHR or control siRNA and incubated for 5 days in the presence or absence of 10 nM doxorubicin.
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related (VHR) [16–18] and MAPK phosphatase (MKP3)
[19], we investigated VHR and MKP3 as possible targets of
caRhoA-induced dephosphorylation of Erk. Western blot
analysis revealed that introduction of siVHR or siMKP3 eﬃ-
ciently decreased the expression of the target protein and in-
duced senescence-like arrest in PC-3 cells (Fig. 4A). Since
Erk requires both Tyr and Thr phosphorylation for full activa-
tion [20], we next investigated the eﬀect of okadaic acid, a spe-
ciﬁc inhibitor for protein Ser/Thr phosphatase 2A (PP2A) [21],
on Erk phosphorylation and senescence-like arrest. Exposure
of cells to okadaic acid induced Erk phosphorylation and
growth arrest, as shown in Fig. 4B. To investigate the possible
involvement of RhoA activation and/or phosphatase in this ef-
fect, we tested whether phosphatase activity could be modu-
lated by caRhoA in this system. As shown in Fig. 4C,
caRhoA expression signiﬁcantly prevented doxorubicin-in-
duced decrease in phosphatase activity. However, siVHR-in-
duced senescence-like arrest was not reversed by caRhoA
(Fig. 4D); this is consistent with the cell cycle arrest induced
by siVHR in the presence of caRhoA expression (data not
shown), indicating that phosphatase might be downstream of
RhoA-mediated signal transduction.4. Discussion
In this study, we demonstrated that inhibition of RhoA
activity induced senescence-like arrest in a human prostate car-
cinoma cell line, and found that phosphatase-mediated
dephosphorylation of ERK was critical for RhoA-mediated
inhibition of growth arrest.RhoA, an important small GTPase, modulates cell cycle-reg-
ulatory proteins and cellular proliferation [22,23]. In our sys-
tem, we observed a protective eﬀect against DNA damage-
induced growth arrest when PC-3 cells were transfected with
caRhoA or co-incubated with inhibitors of Erk. Therefore,
we speculated that RhoA activation might aﬀect growth arrest
by modulating phosphatase.
The MAPKs, Erk, Jnk and p38, are activated by dual phos-
phorylation of a tyrosine and a threonine residue in the Thr-X-
Tyr motif [24]. Because phosphorylation of both Thr and Tyr
in the activation loop is required for maintenance of optimal
MAPK activity, MAPK inactivation may involve Ser/Thr pro-
tein phosphatases (e.g. PP1, PP2A, PP2B, PP2Ca, and kPP),
protein tyrosine phosphatases (e.g. PTP1B and CD45), and
dual speciﬁcity phosphatases (e.g. VHR, MKP3, and
MKP5). Among these phosphatases, VHR, MPK3 and
PP2A have been shown to display exquisite speciﬁcity for
ERK in their substrate recognition [16,18,19]. As inhibition
of PP2A, VHR or MKP3 induced cellular senescence, it was
tempting to determine the direct involvement of RhoA by eval-
uating phosphatase activity according to caRhoA expression.
Doxorubicin decreases phosphatase activity, however, activity
of phosphatase was sustained in caRhoA-expressing PC-3 cells
even in the presence of doxorubicin. This result may provide a
partial mechanistic explanation for the resistance of caRhoA-
expressing PC-3 cells to doxorubicin-induced growth arrest.
Our ﬁnding that senescence-like arrest is induced upon inacti-
vation of these phosphatases serves to further underscore the
importance of phosphatases inhibition in RhoA-active cancer
cells. As siVHR-induced cell cycle arrest in the presence of
caRhoA, phosphatase might be downstream of RhoA signal-
ing. Therefore, although the clinical implication of tumor cell
3804 C. Park et al. / FEBS Letters 581 (2007) 3800–3804senescence is yet to be determined, it will be of particular inter-
est to clarify if phosphatase inhibition may be employed for
RhoA-active cancers in future cancer therapeutics.
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